St. Jude Care & Treatment

Menu

Close

Recruiting

AML23: Venetoclax and Conventional Chemotherapy for Acute Myeloid Leukemia

About this study

Acute myeloid leukemia (AML) is a kind of cancer that starts in the bone marrow. The bone marrow lies inside the large bones of the body and makes blood cells. Some of these cells can change and become abnormal, grow quickly, and crowd out the normal blood cells so they do not work as they should. AML treatment usually uses chemotherapy drugs to kill the leukemia cells.

In this study, scientists will add a drug called venetoclax to chemotherapy to treat newly diagnosed AML in children and young adults. Scientists hope that venetoclax will help improve the chances of long-term remission (no evidence of leukemia) in these patients. The U.S. Food and Drug Administration (FDA) has approved venetoclax to treat adults with AML. The drug has not yet been approved to treat AML in children.

A previous study found that venetoclax was safe and active when given to children who had AML that came back (relapsed) or resisted other treatments.

Eligibility overview

  • Newly diagnosed with AML
  • Older than 28 days and younger than 22 years
  • No earlier treatment for AML
  • Not pregnant
  • Using birth control if capable of having children

Request a referralLearn about clinical research

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Overview

Full title:

A Collaborative Phase 2 Study of Venetoclax in Combination with Conventional Chemotherapy in Pediatric Patients with Acute Myeloid Leukemia

Study goal:

Study the side effects of using venetoclax and chemotherapy to treat children with AML; learn more about how this treatment works

Diagnosis:

Acute myeloid leukemia (AML)

Age:

Older than 28 days and younger than 22 years

Clinical trials categories:

Childhood Cancer Leukemia Acute Myeloid Leukemia (AML)

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.

 

Learn more